Abliva targets SEK 200 million raise to fund the KL1333 Phase 2/3 study to interim analysis
Abliva AB (Nasdaq Stockholm: ABLI) today announced that it intends to raise a financing round of SEK 200 million to provide the company with the capital necessary to run the Phase 2/3 study with KL133 ...